Prospect Of Biosimilar-To-Biosimilar Switching Spurs Call For Postmarketing Data
US FDA questions innovator push of data to instill confidence that pharmacy-level switching between biosimilars interchangeable with same reference biologic; Janssen and others say agency needs to educate prescribers and pharmacists that an interchangeability designation applies only to a biosimilar and its reference product.
